Discovery of efficacious pseudomonas aeruginosa-targeted siderophore-conjugated monocarbams by application of a semi-mechanistic pharmacokinetic/pharmacodynamic model

Journal of Medicinal Chemistry

Volumn 58, Issue 5, 2015, Pages 2195-2205

  Murphy Benenato, Kerry E ^a,c   Bhagunde, Pratik R ^a,d   Chen, April ^a   Davis, Hajnalka E ^a   Durand Réville, Thomas F ^a   Ehmann, David E ^a   Galullo, Vincent ^a   Harris, Jennifer J ^a,e   Hatoum Mokdad, Holia ^a   Jahić, Haris ^a   Kim, Aryun ^a   Manjunatha, M R ^b   Manyak, Erika L ^b,f   Mueller, John ^a   Patey, Sara ^a   Quiroga, Olga ^a   Rooney, Michael ^a   Sha, Li ^a   Shapiro, Adam B ^a   Sylvester, Mark ^a   Tan, Beesan ^a,g   Tsai, Andy S ^a,g   Uria Nickelsen, Maria ^a,g   Wu, Ye ^a   Zambrowski, Mark ^a,h   Zhao, Shannon X ^a   more..

^a Infection Innovative Medicines ^*  (United States)

^b ASTRAZENECA   (United Kingdom)

^c MODERNA THERAPEUTICS   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

^e Experimental Station   (United States)

^f AGIOS PHARMACEUTICALS   (United States)

^g PFIZER INC   (United States)

^h NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM DERIVATIVE; CARBAPENEM DERIVATIVE; SIDEROPHORE; SIDEROPHORE CONJUGATED MONOCARBAM; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BETA LACTAMASE; MONOBACTAM DERIVATIVE;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; IRON TRANSPORT; MALE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PREDICTION; PSEUDOMONAS AERUGINOSA; RAT; ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; METABOLISM; MICROBIOLOGY; PSEUDOMONAS INFECTIONS; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; DRUG DISCOVERY; HUMANS; MALE; MONOBACTAMS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RATS; RATS, WISTAR; SIDEROPHORES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84924706111     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501506f     Document Type: Article

References (56)

1. Giamarellou, H.; Poulakou, G. Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 2009, 69, 1879-1901
2. Rossolini, G. M.; Mantengoli, E. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa Clin. Microbiol. Infect. 2005, 11 (Suppl. 4) 17-32
3. Livermore, D. M. Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 2009, 64 (Suppl. 1) i29-36
4. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discovery 2007, 6, 29-40
5. Xu, Z. Q.; Flavin, M. T.; Flavin, J. Combating multidrug-resistant Gram-negative bacterial infections Expert Opin. Invest. Drugs 2014, 23, 163-182
6. Fisher, J. F.; Meroueh, S. O.; Mobashery, S. Bacterial resistance to β-lactam antibiotics: compelling opportunism, compelling opportunity Chem. Rev. 2005, 105, 395-424
7. Lagace-Wiens, P.; Rubinstein, E. Adverse reactions to β-lactam antimicrobials Expert Opin. Drug Saf. 2012, 11, 381-399
8. Sauvage, E.; Kerff, F.; Terrak, M.; Ayala, J. A.; Charlier, P. The penicillin-binding proteins: structure and role in peptidoglycan biosynthesis FEMS Microbiol. Rev. 2008, 32, 234-258
9. Frere, J.-M.; Page, M. G. P. Penicillin-binding proteins: evergreen drug targets Curr. Opin. Pharmacol. 2014, 18, 112-119
10. Moyá, B.; Beceiro, A.; Cabot, G.; Juan, C.; Zamorano, L.; Alberti, S.; Oliver, A. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities Antimicrob. Agents Chemother. 2012, 56, 4771-4778
11. Shahid, M.; Sobia, F.; Singh, A.; Malik, A.; Khan, H. M.; Jonas, D.; Hawkey, P. M. Beta-lactams and beta-lactamase-inhibitors in current-or potential-clinical practice: a comprehensive update Crit. Rev. Microbiol. 2009, 35, 81-108
12. Drusano, G. L. Pharmacokinetics and pharmacodynamics of antimicrobials Clin. Infect. Dis. 2007, 45 (Suppl. 1) S89-95
13. Llarrull, L. I.; Testero, S. A.; Fisher, J. F.; Mobashery, S. The future of the β-lactams Curr. Opin. Microbiol. 2010, 13, 551-557
14. Bush, K.; Macielag, M. J. New β-lactam antibiotics and β-lactamase inhibitors Expert Opin. Ther. Pat. 2010, 20, 1277-1293
15. Bonnefoy, A.; Dupuis-Hamelin, C.; Steier, V.; Delachaume, C.; Seys, C.; Stachyra, T.; Fairley, M.; Guitton, M.; Lampilas, M. In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor J. Antimicrob. Chemother. 2004, 54, 410-417
16. Lister, P. D.; Wolter, D. J.; Hanson, N. D. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms Clin. Microbiol. Rev. 2009, 22, 582-610
17. Walsh, T. R. Emerging carbapenemases: a global perspective Int. J. Antimicrob. Agents 2010, 36 (Suppl. 3) S8-14
18. Diene, S. M.; Rolain, J. M. Carbapenemase genes and genetic platforms in Gram-negative bacilli: Enterobacteriaceae, Pseudomonas and Acinetobacter species Clin. Microbiol. Infect. 2014, 20, 831-8
19. Drawz, S. M.; Papp-Wallace, K. M.; Bonomo, R. A. New β-lactamase inhibitors: a therapeutic renaissance in an MDR world Antimicrob. Agents Chemother. 2014, 58, 1835-1846
20. Nordmann, P.; Poirel, L.; Walsh, T. R.; Livermore, D. M. The emerging NDM carbapenemases Trends Microbiol. 2011, 19, 588-595
21. Sykes, R. B.; Koster, W. H.; Bonner, D. P. The new monobactams: chemistry and biology J. Clin. Pharmacol. 1988, 28, 113-119
22. Barbachyn, M. R.; Tuominen, T. C. Synthesis and structure-activity relationships of monocarbams leading to U-78608 J. Antibiot. (Tokyo) 1990, 43, 1199-1203
23. Flanagan, M. E.; Brickner, S. J.; Lall, M.; Casavant, J.; Deschenes, L.; Finegan, S. M.; George, D. M.; Granskog, K.; Hardink, J. R.; Huband, M. D.; Hoang, T.; Lamb, L.; Marra, A.; Mitton-Fry, M.; Mueller, J. P.; Mullins, L. M.; Noe, M. C.; O'Donnell, J. P.; Pattavina, D.; Penzien, J. B.; Schuff, B. P.; Sun, J.; Whipple, D. A.; Young, J.; Gootz, T. D. Preparation, Gram-negative antibacterial activity, and hydrolytic stability of novel siderophore-conjugated monocarbam diols ACS Med. Chem. Lett. 2011, 2, 385-390
24. King, D. T.; Worrall, L. J.; Gruninger, R.; Strynadka, N. C. New Delhi metallo-β-lactamase: structural insights into β-lactam recognition and inhibition J. Am. Chem. Soc. 2012, 134, 11362-11365
25. Wang, J. F.; Chou, K. C. Metallo-β-lactamases: structural features, antibiotic recognition, inhibition, and inhibitor design Curr. Top. Med. Chem. 2013, 13, 1242-1253
26. Page, M. G.; Dantier, C.; Desarbre, E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli Antimicrob. Agents Chemother. 2010, 54, 2291-2302
27. Brown, M. F.; Mitton-Fry, M. J.; Arcari, J. T.; Barham, R.; Casavant, J.; Gerstenberger, B. S.; Han, S.; Hardink, J. R.; Harris, T. M.; Hoang, T.; Huband, M. D.; Lall, M. S.; Lemmon, M. M.; Li, C.; Lin, J.; McCurdy, S. P.; McElroy, E.; McPherson, C.; Marr, E. S.; Mueller, J. P.; Mullins, L.; Nikitenko, A. A.; Noe, M. C.; Penzien, J.; Plummer, M. S.; Schuff, B. P.; Shanmugasundaram, V.; Starr, J. T.; Sun, J.; Tomaras, A.; Young, J. A.; Zaniewski, R. P. Pyridone-conjugated monobactam antibiotics with Gram-negative activity J. Med. Chem. 2013, 56, 5541-5552
28. Starr, J.; Brown, M. F.; Aschenbrenner, L.; Caspers, N.; Che, Y.; Gerstenberger, B. S.; Huband, M.; Knafels, J. D.; Lemmon, M. M.; Li, C.; McCurdy, S. P.; McElroy, E.; Rauckhorst, M. R.; Tomaras, A. P.; Young, J. A.; Zaniewski, R. P.; Shanmugasundaram, V.; Han, S. Siderophore receptor-mediated uptake of lactivicin analogues in Gram-negative bacteria J. Med. Chem. 2014, 57, 3845-3855
29. Schaible, U. E.; Kaufmann, S. H. Iron and microbial infection Nat. Rev. Microbiol. 2004, 2, 946-953
30. Braun, V.; Hantke, K. Recent insights into iron import by bacteria Curr. Opin. Chem. Biol. 2011, 15, 328-334
31. Noinaj, N.; Guillier, M.; Barnard, T. J.; Buchanan, S. K. TonB-dependent transporters: regulation, structure, and function Annu. Rev. Microbiol. 2010, 64, 43-60
32. Foley, T. L.; Simeonov, A. Targeting iron assimilation to develop new antibacterials Expert Opin. Drug Discovery 2012, 7, 831-847
33. Mislin, G. L.; Schalk, I. J. Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa Metallomics 2014, 6, 408-420
34. Sykes, R. B.; Bonner, D. P.; Bush, K.; Georgopapdakou, N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic Gram-negative bacteria Antimicrob. Agents Chemother. 1982, 21, 85-92
35. Shapiro, A. B.; Gu, R. F.; Gao, N.; Livchak, S.; Thresher, J. Continuous fluorescence anisotropy-based assay of BOCILLIN FL penicillin reaction with penicillin binding protein 3 Anal. Biochem. 2013, 439, 37-43
36. McPherson, C. J.; Aschenbrenner, L. M.; Lacey, B. M.; Fahnoe, K. C.; Lemmon, M. M.; Finegan, S. M.; Tadakamalla, B.; O'Donnell, J. P.; Mueller, J. P.; Tomaras, A. P. Clinically relevant Gram-negative resistance mechanisms have no effect on the efficacy of MC-1, a novel siderophore-conjugated monocarbam Antimicrob. Agents Chemother. 2012, 56, 6334-6342
37. Tomaras, A. P.; Crandon, J. L.; McPherson, C. J.; Banevicius, M. A.; Finegan, S. M.; Irvine, R. L.; Brown, M. F.; O'Donnell, J. P.; Nicolau, D. P. Adaptation-based resistance to siderophore-conjugated antibacterial agents by Pseudomonas aeruginosa Antimicrob. Agents Chemother. 2013, 57, 4197-4207
38. Nielsen, E. I.; Friberg, L. E. Pharmacokinetic-pharmacodynamic modeling of antibacterial drugs Pharmacol. Rev. 2013, 65, 1053-1090
39. Drusano, G. L. Prevention of resistance: a goal for dose selection for antimicrobial agents Clin. Infect. Dis. 2003, 36, S42-50
40. Trainor, G. L. The importance of plasma protein binding in drug discovery Expert Opin. Drug Discovery 2007, 2, 51-64
41. Woulfe, S. R.; Miller, M. J. The synthesis of substituted 3(S)-(acylamino)-2-oxo-1-azetidinyl]thio]acetic acids J. Org. Chem. 1986, 51, 3133-3139
42. Brickner, S. J.; Flanagan, M. E.; Lall, M. S. Monocarbams. WO2010070523A1, 2010.
43. Han, S.; Zaniewski, R. P.; Marr, E. S.; Lacey, B. M.; Tomaras, A. P.; Evdokimov, A.; Miller, J. R.; Shanmugasundaram, V. Structural basis for effectiveness of siderophore-conjugated monocarbams against clinically relevant strains of Pseudomonas aeruginosa Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 22002-22007
44. Barbachyn, M. R.; Brickner, S. J.; Thomas, R. C. Antibiotic sulfonylaminocarbonyl activated beta-lactams. EP281289A1, 1988.
45. Mitton-Fry, M. J.; Arcari, J. T.; Brown, M. F.; Casavant, J. M.; Finegan, S. M.; Flanagan, M. E.; Gao, H.; George, D. M.; Gerstenberger, B. S.; Han, S.; Hardink, J. R.; Harris, T. M.; Hoang, T.; Huband, M. D.; Irvine, R.; Lall, M. S.; Megan Lemmon, M.; Li, C.; Lin, J.; McCurdy, S. P.; Mueller, J. P.; Mullins, L.; Niosi, M.; Noe, M. C.; Pattavina, D.; Penzien, J.; Plummer, M. S.; Risley, H.; Schuff, B. P.; Shanmugasundaram, V.; Starr, J. T.; Sun, J.; Winton, J.; Young, J. A. Novel monobactams utilizing a siderophore uptake mechanism for the treatment of Gram-negative infections Bioorg. Med. Chem. Lett. 2012, 22, 5989-5994
46. Murphy-Benenato, K.; Dangel, B.; Davis, H. E.; Durand-Reville, T. F.; Ferguson, A.; Jahić, H.; Mueller, J. P.; Quiroga, O.; Sha, L.; Sylvester, M.; Wu, F.; Zambrowski, M.; Zhao, S. X. Unpublished results.
47. Naas, T.; Poirel, L.; Nordmann, P. Minor extended-spectrum β-lactamases Clin. Microbiol. Infect. 2008, 14 (Suppl. 1) 42-52
48. Turnidge, J. D. The pharmacodynamics of beta-lactams Clin. Infect. Dis. 1998, 27, 10-22
49. Andes, D.; Craig, W. A. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations Antimicrob. Agents Chemother. 1998, 42, 2375-2379
50. Tam, V. H.; Schilling, A. N.; Nikolaou, M. Modelling time-kill studies to discern the pharmacodynamics of meropenem J. Antimicrob. Chemother. 2005, 55, 699-706
51. Tam, V. H.; Kabbara, S.; Vo, G.; Schilling, A. N.; Coyle, E. A. Comparative pharmacodynamics of gentamicin against Staphylococcus aureus and Pseudomonas aeruginosa Antimicrob. Agents Chemother. 2006, 50, 2626-2631
52. Tam, V. H.; Ledesma, K. R.; Vo, G.; Kabbara, S.; Lim, T. P.; Nikolaou, M. Pharmacodynamic modeling of aminoglycosides against Pseudomonas aeruginosa and Acinetobacter baumannii: identifying dosing regimens to suppress resistance development Antimicrob. Agents Chemother. 2008, 52, 3987-3993
53. Tam, V. H.; Ledesma, K. R.; Schilling, A. N.; Lim, T.-P.; Yuan, Z.; Ghose, R.; Lewis, R. E. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing Diagn. Microbiol. Infect. Dis. 2009, 64, 427-433.53
54. Kim, A.; Crandon, J.; Gorseth, E.; Blinn, C.; Patey, S.; Kutschke, A.; Chen, A.; Rooney, M.; Benenato, K.; Ehmann, D.; Eakin, A.; Nicolau, D. In Vivo Pharmacodynamics of a Siderophore-Conjugated Monocarbam in Pseudomonas aeruginosa (PA): Assessing the Risk of Attenuated Efficacy; Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington DC, Sept 5-9, 2014; American Society of Microbiology: Washington, DC, 2014.
55. Breuer, H. Bactericides for mammals and humans. US4772693A, 1988.
56. Nakayama, Y.; Sanemitsu, Y.; Mizutani, M.; Yoshioka, H. 1,2,4-Triazines. 1. A convenient synthesis of 4,5-dihydro-1,2,4-triazin-3-(2 H)one and its 6-substituted derivatives J. Heterocycl. Chem. 1981, 18, 631-2